Abstract
Dendritic cells (DCs) are the most effective antigen presenting cells (APCs) to elicit both primary and secondary T-cell response that is critical for antitumor immunity and elimination of intracellular pathogens. Therefore, DCs pulsed ex vivo with antigens have the potential used as cell-based vaccines against tumors. Viral vectors derived from adenoviruses have been extensively used to pulse DCs ex vivo by delivering genes encoding immunomodulatory molecules and tumor antigens to DCs since these vectors are relatively safe, effective in inducing the maturation of DCs, and can accommodate large expression cassettes encoding antigens. One of the hurdles for gene delivery to DCs by adenovirus (Ad) vectors, however, is low transfection efficiency of DCs due to the paucity of Ad receptor on DCs. To overcome this obstacle, targeted Ad vectors have been made by modifying viral capsid proteins. These targeted Ad vectors not only enhance the gene delivery to DCs, but also allow in vivo gene delivery to DCs, thus avoiding ex vivo manipulation of DCs.
Keywords: dendritic cells, adenovirus, gene delivery, vaccine, tumor antigen
Current Gene Therapy
Title: Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer
Volume: 5 Issue: 2
Author(s): Qiaohua Wu, Dajing Xia, Svein Carlsen and Jim Xiang
Affiliation:
Keywords: dendritic cells, adenovirus, gene delivery, vaccine, tumor antigen
Abstract: Dendritic cells (DCs) are the most effective antigen presenting cells (APCs) to elicit both primary and secondary T-cell response that is critical for antitumor immunity and elimination of intracellular pathogens. Therefore, DCs pulsed ex vivo with antigens have the potential used as cell-based vaccines against tumors. Viral vectors derived from adenoviruses have been extensively used to pulse DCs ex vivo by delivering genes encoding immunomodulatory molecules and tumor antigens to DCs since these vectors are relatively safe, effective in inducing the maturation of DCs, and can accommodate large expression cassettes encoding antigens. One of the hurdles for gene delivery to DCs by adenovirus (Ad) vectors, however, is low transfection efficiency of DCs due to the paucity of Ad receptor on DCs. To overcome this obstacle, targeted Ad vectors have been made by modifying viral capsid proteins. These targeted Ad vectors not only enhance the gene delivery to DCs, but also allow in vivo gene delivery to DCs, thus avoiding ex vivo manipulation of DCs.
Export Options
About this article
Cite this article as:
Wu Qiaohua, Xia Dajing, Carlsen Svein and Xiang Jim, Adenovirus-mediated Transgene-engineered Dendritic Cell Vaccine of Cancer, Current Gene Therapy 2005; 5 (2) . https://dx.doi.org/10.2174/1566523053544272
DOI https://dx.doi.org/10.2174/1566523053544272 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Identification of Imidazoquinoline Derivatives as Potent Antiglioma Agents
Medicinal Chemistry Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods
Current Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Interpreting the Mechanisms by which Integrins Promote the Differentiation of Mesenchymal Stem Cells and Integrin Application Prospects
Current Stem Cell Research & Therapy Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Aquaporins and Glia
Current Neuropharmacology Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry EDITORIAL (Hot Topic: Cancer Chemoresistance and DNA Repair)
Current Medicinal Chemistry Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews Translating Mismatch Repair Mechanism into Cancer Care
Current Drug Targets Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews